H. Robert Horvitz

David H. Koch Professor of Biology, MIT

Investigator of the Howard Hughes Medical Institute

Member of the MIT McGoven Institute for Brain Research

Member of the MIT Koch Institute for Integrative Cancer Research

Department: 

  • Biology

Room: 

68-425
(617)-253-4671

Faculty Bio: 

H. Robert Horvitz is the David H. Koch Professor of Biology at MIT, an Investigator of the Howard Hughes Medical Institute, a Member of the MIT McGovern Institute for Brain Research and a Member of the MIT Koch Institute for Integrative Cancer Research.  Dr. Horvitz received S.B. degrees in Mathematics and in Economics from MIT in 1968.  He performed his graduate studies of phage T4-induced modifications of E. coli RNA polymerase at Harvard University in the laboratories of Drs. James Watson and Walter Gilbert.  He received his Ph.D. in Biology in 1974. Dr. Horvitz then began his studies of C. elegans as a postdoctoral fellow with Dr. Sydney Brenner at the Medical Research Council Laboratory of Molecular Biology in Cambridge, England.  Since 1978, Dr. Horvitz has been an Assistant, Associate and Full Professor in the Department of Biology at MIT.  His research involving C. elegans has helped define evolutionarily conserved molecular genetic pathways important in human biology and human disease, including the pathway responsible for programmed cell death, or apoptosis.

Dr. Horvitz is actively interested in science education and in the role of science in informing public policy.  He is Chairman of the Board of Trustees of the Society for Science and the Public (SSP), which runs science competitions for high school and middle school students ­­– the Regeneron/Intel/Westinghouse Science Talent Search (STS), the Intel Science and Engineering Fair (ISEF), and the Broadcom Math, Applied Science, Technology, and Engineering for Rising Stars (MASTERS) program; SSP also publishes Science News, which informs the lay public about the frontiers of science.  Dr. Horvitz is a member of the Advisory Committee to the Chair of the Coalition for the Life Sciences (CLS), an alliance of biomedical professional organizations working together to advocate for the support of basic biological research to Congress.  Dr. Horvitz is a member of the Board of Trustees of the Massachusetts General Hospital.  He was President of the Genetics Society of America and a member of the Advisory Council to the Director (ACD) of the NIH and of the Council of the National Academy of Medicine.  Dr. Horvitz has been a consultant to pharmaceutical, biotechnology and venture capital companies.

Research Areas: 

Research Summary: 

Overview:

How do genes control animal development and behavior?  To answer this question, we use the experimentally tractable nematode Caenorhabditis elegans to identify and analyze molecular and cellular pathways involved in these important areas of biology, with the goal of discovering fundamental biological mechanisms and revealing insights into human diseases.

Research Summary:

Programmed Cell Death.  Naturally-occurring or “programmed” cell deaths play major roles in animal development and homeostasis, and abnormalities in programmed cell deaths are causally involved in numerous human diseases, including cancer and certain neurodegenerative disorders.  Diverse developmental events involve programmed cell deaths.  The loss of the tadpole tail during metamorphosis into a frog, the sculpting of human fingers and toes in utero, the seasonal degeneration of the brain region that drives birdsong, and the elimination of self-reactive cells in the immune system all provide examples of programmed cell death.  Cells that die by programmed cell death undergo a process known as apoptosis, defined by morphological and ultrastructural characteristics.  Abnormalities in programmed cell death are causally involved in numerous human diseases, including certain neurodegenerative disorders and cancer.  We discovered that the 131 programmed cell deaths that occur during C. elegans development are controlled by a specific set of killer and protector genes, and we defined the canonical molecular genetic pathway for programmed cell death.  This pathway of cellular suicide subsequently proved to be conserved in other animals, including humans, and the human homologs of genes we discovered are now therapeutic targets for human diseases.  One of the C. elegans killer genes, ced-3, encodes the founding member of a family of proteases known as caspases, key drivers of apoptotic cell death.  We recently discovered that in C. elegans some cells die in the absence of caspases.  We currently are exploring a number of major problems in the field of cell death:

  • how specific cells decide whether to live or die
  • how caspase activation kills cells
  • how neighboring cells recognize and engulf dying cells to eliminate them
  • mechanistic differences among cell suicides, murders, induced suicides and assisted suicides
  • mechanisms responsible for caspase-independent apoptosis
  • how caspase-dependent and caspase-independent cell-death pathways are coordinated within single cells         

Cell Lineage and Cell Fate.  Animal development begins with the fertilized egg and proceeds through many cell divisions to generate a great variety of different cell types.  How cell diversity is generated during development is a fundamental issue in biology.  C. elegans has only 959 somatic cells and a known cell lineage, facilitating analyses of development at the single-cell level.  We have identified mechanisms that make daughter cells different from mother cells, that make sister cells different from each other or that break left-right developmental symmetry.  Our studies of the induction of vulval development helped define the Ras signal transduction pathway, key in cancer biology.  We defined the heterochronic pathway, which controls developmental timing and led to the discovery of microRNAs.  We currently are analyzing the following issues involving cell lineage and cell fate:

  • how neurons can be generated from mesodermal cell lineages
  • mechanisms that control the developmental timing of the expression of cell fates
  • how epigenetic factors determine cell fates
  • mechanisms that control the maintenance, as opposed to the establishment, of cell fates

Behavior.  To explore the molecular, cellular and circuit bases of nervous system function, we are analyzing the coordinately controlled C. elegans behaviors of feeding, egg laying and locomotion.  From our studies of behavior we have identified founding members of the RGS protein family, which regulates signaling from G-protein coupled receptors, and the EGLN family of dioxygenases, which control the HIF-VHL pathway that is vital in cellular and organismic O2 sensing and is a therapeutic target in cancer.  We also identified a novel class of neurotransmitter receptors, chloride channels gated by biogenic amines, and a new neurotransmitter, tyramine.  Our current studies include the following problems:

  • how the EGL-9/HIF pathway, key in cancer biology, controls animal behavior in response to changes in O2 concentration
  • how neuropeptides and biogenic amines modulate animal behavior and behavioral state
  • how neural regulation in response to noxious stimuli convert swallowing to spitting behavior
  • how maternal stress drives signaling from the nervous system to the germline to confer stress-resistance to progeny
  • mechanisms that control muscle metabolic homeostasis in response to changing environmental conditions
  • mechanisms that function in classical conditioning
  • how hyperglycemia drives neuropathy

Amyotrophic lateral sclerosis (ALS).  We have long studied the human neurodegenerative disease ALS.  In collaborative studies, we have identified and characterized many ALS genes, including the first known ALS gene, SOD-1.  We are now analyzing:

  • the function of the C. elegans ortholog of the human gene C9orf72, in which hexanucleotide-repeat expansion disease alleles cause both ALS and frontotemporal dementia.